loading...| Preferred Name |
atorvastatin calcium |
|
| Synonyms |
atorvastatin calcium trihydrate |
|
| Definitions |
The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C28837" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C28837" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000460239 |
|
| altLabel |
atorvastatin calcium trihydrate Lipitor CI-981 |
|
| CAS Registry |
344423-98-9 134523-03-8 |
|
| cui |
C3463896 C0593906 C0286650 C0082029 |
|
| DATE FIRST PUBLISHED |
2005-12-22 |
|
| Date last modified |
2017-12-14 |
|
| definition |
The calcium salt of atorvastatin, a synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent increases the number of LDL receptors on hepatic cell surfaces, enhancing the uptake and catabolism of LDL and reducing LDL production and the number of LDL particles, and lowers plasma cholesterol and lipoprotein levels. Like other statins, atorvastatin may also display direct antineoplastic activity, possibly by inhibiting farnesylation and geranylgeranylation of proteins such as small GTP-binding proteins, which may result in the arrest of cells in the G1 phase of the cell cycle. This agent may also sensitize tumor cells to cyctostatic drugs, possibly through the mTOR-dependent inhibition of Akt phosphorylation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C28837" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C28837" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C28837 |
|
| notation |
CDR0000460239 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
atorvastatin calcium |
|
| tui |
T109 T121 |